GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Mar 2024 09:30 AM
RNS
New Phase III Jemperli data in endometrial cancer
13 Mar 2024 03:48 PM
RNS
Director/PDMR Shareholding
13 Mar 2024 03:48 PM
RNS
Director/PDMR Shareholding
08 Mar 2024 05:12 PM
RNS
Board Committee Change
07 Mar 2024 07:00 AM
RNS
GSK announces positive Blenrep DREAMM-8 results
06 Mar 2024 04:00 PM
RNS
ViiV LAI vs oral SOC data in adherence-challenged
05 Mar 2024 05:24 PM
RNS
GSK Annual Report 2023 on Form 20-F
05 Mar 2024 07:00 AM
RNS
New ViiV LA formulation potential 4-month dosing
01 Mar 2024 03:00 PM
RNS
Total Voting Rights
01 Mar 2024 12:15 PM
RNS
GSK publishes Annual Report 2023
29 Feb 2024 07:05 AM
RNS
Directorate Change
29 Feb 2024 07:00 AM
RNS
Statement: Zantac (ranitidine) litigation
26 Feb 2024 03:30 PM
RNS
Director/PDMR Shareholding
26 Feb 2024 07:00 AM
RNS
GSK announces positive EAGLE-1 headline results
22 Feb 2024 03:30 PM
RNS
Director/PDMR Shareholding
21 Feb 2024 07:00 AM
RNS
ViiV LAI superior to orals in adherence-challenged
20 Feb 2024 09:01 AM
RNS
Julie Brown - External Appointment
19 Feb 2024 03:30 PM
RNS
Director/PDMR Shareholding
15 Feb 2024 03:32 PM
RNS
Director/PDMR Shareholding
15 Feb 2024 07:00 AM
RNS
GSK completes acquisition of Aiolos Bio
13 Feb 2024 04:45 PM
RNS
Director/PDMR Shareholding - Replacement
13 Feb 2024 03:40 PM
RNS
Director/PDMR Shareholding
13 Feb 2024 03:35 PM
RNS
Director/PDMR Shareholding
13 Feb 2024 03:30 PM
RNS
Director/PDMR Shareholding
12 Feb 2024 03:39 PM
RNS
Director/PDMR Shareholding
12 Feb 2024 03:38 PM
RNS
Director/PDMR Shareholding
12 Feb 2024 03:26 PM
RNS
Director/PDMR Shareholding
12 Feb 2024 07:00 AM
RNS
US FDA Fast Track designation for bepirovirsen
06 Feb 2024 07:10 AM
RNS
FDA accepts Arexvy filing for adults 50-59 at risk
06 Feb 2024 07:05 AM
RNS
Shingrix 18+ at risk China filing review accepted
06 Feb 2024 07:00 AM
RNS
GSK presents positive DREAMM-7 phase III data
01 Feb 2024 03:30 PM
RNS
Director/PDMR Shareholding
01 Feb 2024 03:00 PM
RNS
Total Voting Rights
01 Feb 2024 07:00 AM
RNS
Statement: Zantac (ranitidine) litigation
31 Jan 2024 07:00 AM
RNS
Final Results
29 Jan 2024 07:05 AM
RNS
EMA accepts Arexvy filing for adults 50-59 at risk
29 Jan 2024 07:00 AM
RNS
European Commission authorises Omjjara in the EU
19 Jan 2024 03:30 PM
RNS
Director/PDMR Shareholding
18 Jan 2024 05:00 PM
RNS
Holding(s) in Company
17 Jan 2024 03:30 PM
RNS
Director/PDMR Shareholding
17 Jan 2024 07:00 AM
RNS
GSK completes sale of shares in Haleon plc
16 Jan 2024 04:40 PM
RNS
GSK announces intention to sell shares in Haleon
16 Jan 2024 03:30 PM
RNS
Director/PDMR Shareholding
10 Jan 2024 07:00 AM
RNS
Nucala approved in China for use in severe asthma
09 Jan 2024 07:00 AM
RNS
GSK enters agreement to acquire Aiolos Bio
02 Jan 2024 03:00 PM
RNS
Total Voting Rights
21 Dec 2023 03:30 PM
RNS
Director/PDMR Shareholding
20 Dec 2023 04:44 PM
RNS
Publication of EMTN Suppl.Prospcts
18 Dec 2023 07:00 AM
RNS
Jemperli plus Zejula Trial Meets Endpoint
13 Dec 2023 03:30 PM
RNS
Director/PDMR Shareholding

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

UK 100

Latest directors dealings